Investment helps examine evaluating three novel, non-invasive neuroimaging biomarkers of Alzheimer’s illness and dementia
SHERBROOKE, QC, Oct. 24, 2023 /PRNewswire/ — Imeka, the main neuroimaging firm combining diffusion imaging and AI to map white matter microstructure, in the present day introduced an funding from the Alzheimer’s Drug Discovery Foundation (ADDF) to speed up the event of novel biomarkers for Alzheimer’s illness and associated dementias. The funding will help use of Imeka neuroimaging biomarkers in a large-scale, longitudinal examine of dementia markers and their development from pre-symptomatic levels to the onset of Alzheimer’s illness and different varieties of dementia.
“Neuroinflammation has lengthy been an space of curiosity in Alzheimer’s drug growth, however with out the correct biomarkers to watch irritation ranges within the mind, researchers will wrestle to validate their findings and showcase the efficacy of their medicine,” says Howard Fillit, MD, Co-Founder and Chief Science Officer on the ADDF. “The growth of a novel neuroimaging device, like Imeka’s, is not going to solely show important for bringing neuroinflammatory therapeutics to market, however may even develop the biomarker pipeline to incorporate a number of biomarkers exploring varied pathways, all of which help the biology of getting older strategy—the concept many underlying pathologies result in the onset of the illness.”
Imeka’s proprietary neuroimaging expertise helps pharmaceutical and biotechnology firms establish biomarkers related to neurological circumstances equivalent to Alzheimer’s illness, MS, and Traumatic Brain Injury. Combining AI and neuroimaging, Imeka’s expertise gives extremely localized views of the results of each illness and investigational therapies on white matter, equipping physicians with extra detailed data on the mind to help affected person assessments. As a part of this new venture, Imeka will consider three novel, non-invasive diffusion MRI biomarkers of neuroinflammation, demyelination, and axonal disruption in high-quality Alzheimer’s illness knowledge units as potential non-invasive and more cost effective options to PET scans.
The examine goals embody:
-
Evaluating Imeka’s novel, non-invasive diffusion MRI biomarkers of neuroinflammation, demyelination, and axonal disruption with different imaging and fluid-based biomarkers
-
Confirming the potential of those three measures as monitoring biomarkers for Alzheimer’s illness
-
Comparing Imeka’s biomarkers to a autopsy Alzheimer’s illness mind financial institution
The data gained from this venture shall be introduced into Imeka’s Advanced Neuro Diagnostic Imaging (ANDI) quantitative imaging software program – which just lately acquired 510(k) clearance from the U.S. Food and Drug Administration – serving to radiologists, neurologists, and different medical professionals rapidly translate these helpful insights into scientific apply.
“We are extraordinarily grateful to collaborate with the ADDF on this breakthrough venture,” stated Jean-René Bélanger, Chief Executive Officer at Imeka. “Alzheimer’s is a devastating illness that impacts the on a regular basis lives of tens of millions of individuals and their households. We based Imeka to develop novel, non-invasive neuroimaging applied sciences that may assist seek for and develop cures for Alzheimer’s and different mind illnesses and, finally, to supply scientific instruments that may assist diagnose and monitor neurological illnesses and circumstances in addition to orient therapies and consider their efficacy. The funding from the ADDF will gas analysis that considerably advances our understanding of Alzheimer’s illness. Together, we may help enhance the monitoring of present therapies for Alzheimer’s, speed up the invention of recent therapeutics to stop and deal with the illness, and enhance the general normal of look after each the prognosis and therapy of sufferers.”
“Brain imaging is necessary for detecting and monitoring Alzheimer’s illness, however conventional imaging instruments have largely missed the function of white matter and the usage of MRI as a delicate and particular device to evaluate neuroinflammation and the integrity of axons and myelin. We are excited to collaborate with the ADDF on this venture. The autopsy mind financial institution knowledge and the in-vivo human affected person knowledge used for the validation a part of the venture are of unprecedented worth and high quality,” stated Maxime Descoteaux, Co-Founder and Scientific Advisor at Imeka. “By combining knowledge from this new venture with Imeka’s ANDI quantitative imaging software program, we will equip healthcare practitioners with larger element about white matter by non-invasive, more-reliable imaging. We consider this vital data can improve monitoring in Alzheimer’s illness scientific trials and assist enhance affected person outcomes.”
To be taught extra, please go to www.imeka.ca.
About Imeka
Imeka is the worldwide chief in white matter microstructure imaging, combining superior MRI processing capabilities and synthetic intelligence to convey novel insights to the analysis and scientific communities. The firm has been working with all main pharmaceutical firms growing therapies for neurodegenerative illnesses and is now providing its state-of-the-art expertise to physicians to instantly affect sufferers. Based in Sherbrooke, Quebec, Canada, the corporate additionally has an workplace in Cambridge, Massachusetts. Learn extra at www.imeka.ca.
About The Alzheimer’s Drug Discovery Foundation (ADDF)
Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer’s Drug Discovery Foundation is devoted to quickly accelerating the invention of medicine to stop, deal with and treatment Alzheimer’s illness. The ADDF is the one public charity solely centered on funding the event of medicine for Alzheimer’s, using a enterprise philanthropy mannequin to help analysis in academia and the biotech business. The ADDF’s management and contributions to the sphere have performed a pivotal function in bringing the primary Alzheimer’s PET scan (Amyvid®) and blood check (PrecivityAD®) to market, in addition to fueling the present sturdy and numerous drug pipeline. Through the generosity of its donors, the ADDF has awarded greater than $250 million to fund over 720 Alzheimer’s drug discovery applications, biomarker applications and scientific trials in 19 nations. To be taught extra, please go to: http://www.alzdiscovery.org/.
View unique content material to obtain multimedia:https://www.prnewswire.com/news-releases/imeka-receives-investment-from-alzheimers-drug-discovery-foundation-for-biomarker-development-301963503.html
SOURCE Imeka
